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Classification 
- Primarily described as rhabdoid tumor of the kidney 
(RTK), further extended to tumors of other primary 
sites: extrarenal rhabdoid tumor (ERRT, or malignant 
extrarenal rhabdoid tumor MERT) 
- They present a wide histological, ultrastructural, and 
immunocytochemical spectrum. 
- May represent a heterogeneous group of neoplasms 
and also invite confusion with other renal or extrarenal 
neoplasms, of which is the Favorable Histology Wilms' 
tumor (with a fair prognosis). 
- Finally "composite" extrarenal rhabdoid tumors 
(CERT) with a recognizable "parent" neoplasm 
admixed with MERT appear to be of various origin. 
- The recent finding that hSNF5/INI1is involved in true 
rhabdoid tumors is of paramount importance in this 
context. 




RTK occurs in infancy and early childhood, median 
age is 11 mths; unbalanced sex ratio (1.5M/1F); ERRT 
have been observed in a broader range of patient ags.
Clinics 
Often located in the kidney, may occur in various 
anatomic sites, such as the central nervous system or 
soft tissues. 
Prognosis 
Highly aggressive; 80% mortality rate with frequent 
metastases, predominantly pulmonary; a large study 10 
yrs ago found a better outcome for girls (> 50% 
survival) than for boys (10%). 
Cytogenetics 
Cytogenetics Morphological 
- Normal karyotype or 22q11.2 involvement in a t(Var; 
22)(-;q11.2) or in del(22q). 
- Loss of heterozygosity (LOH) on chromosome 22; 
LOH can also occur at chromosome band 11p15.5, 
indicating that a second gene may also be involved in 
addition in a subset of rhabdoid tumors. 





Found in the rhabdoid tumor predisposition syndrome. 
Somatic mutations 
Mutation and allele loss events in sporadic rhabdoid 
tumors are in accordance with the two-hit model for 
neoplasia, as is found in retinoblastoma. 
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